Mediar is a pre-clinical stage biotechnology company developing therapeutics for the treatment of fibrosis. Its therapeutics target key fibrotic mediator proteins that aid in the development of fibrosis in chronically-damaged organs. The company was founded in 2019 and is headquartered in Cambridge, Massachusetts.
Dren Bio is a biotechnology company with a portfolio of attractive projects focused on powerful protein engineering technologies for the depletion of cells, protein aggregates, and other disease-causing agents. It is a holding company business model aimed at creating value with multiple projects as stand-alone assets.
ImmunOs Therapeutics AG is a clinical-stage biotechnology company focused on discovering and developing next generation and novel human immunomodulatory proteins with a role in both innate and adaptive immunity.Their mission is to develop the next generation of novel therapeutics that will improve the lives of patients with serious disease.
Arkuda Therapeutics is a biotechnology company leveraging new insights into progranulin and lysosomal biology to develop medicines to change the trajectory of neurodegenerative disease. Arkuda’s lead compounds aim to correct progranulin deficiency and lysosomal dysfunction in GRN-related frontotemporal dementia (FTD-GRN), a genetically-defined subtype of frontotemporal dementia caused by an autosomal dominant mutation in the GRN gene.
AmbAgon Therapeutics is a developer of cancer molecule therapeutics. The company offers research of a small molecule that augments a tumor-suppressing protein. AmbAgon Therapeutics was founded by Christian Ottmann, Lucas Brunsveld, and Michelle Arkin.
Tune Therapeutics strives to develop paradigm-changing cell and gene therapies that leverage epigenetic programming for the treatment of devastating diseases.
GraphWear is reinventing the way we map human health. Pioneering a no-needle, no-blood approach to disease monitoring, GraphWear’s technology offers the first genuinely non-invasive method to map patient health, unlocking a new adherence for some of the most significant chronic diseases. By empowering access to accurate and timely health information in an easy-to-use format, GraphWear aims to drive greater efficiency across diagnosis, management, and care. GraphWear is currently in clinical trials for its first target, monitoring glucose levels for diabetes, with additional potential across conditions like heart disease and cancer.
Asher Bio is an information technology company that specializes in the fields of CFO Office transformation, profitability, and cost management. It focuses on building and developing better immunotherapy for cancer. The company was founded in 2019 and headquartered in San Francisco, California.
Shape Therapeutics (ShapeTX) is a biotechnology company with an end-to-end approach to RNA Gene Therapy, potentially enabling the development of cures in neurodegenerative, metabolic and rare genetic diseases through our breakthrough payload, delivery, and manufacturing platform technologies. Our vision is to facilitate adoption of these technologies throughout the industry to develop effective treatments for as many patients as possible.
Glycomine is early-stage biotech working on replacement therapies for rare diseases. There are approximately 7,000 rare disorders worldwide. Each day more are being discovered. 95% of rare diseases have not one single FDA-approved treatment. Glycomine develops therapeutics for diseases that have no treatment options.
Vedere is developing cutting-edge gene therapy products to restore functional vision to patients who have suffered vision loss from Inherited Retinal Degenerations (IRDs), as well as other causes of both genetic and non-genetic vision loss. While the vast majority of ocular gene therapies only limit the rate of inevitable vision loss, we aim to restore lost vision regardless of a patient’s underlying genetics or their stage of disease.
Mediar is a pre-clinical stage biotechnology company developing therapeutics for the treatment of fibrosis. Its therapeutics target key fibrotic mediator proteins that aid in the development of fibrosis in chronically-damaged organs. The company was founded in 2019 and is headquartered in Cambridge, Massachusetts.
Caribou Biosciences is an operator of a medical technology company intended to analyze cell and genome engineering. The company specializes in cellular engineering and analysis based on the CRISPR-Cas9 technology platform which paired with a guide RNA, cuts double-stranded DNA and allows for specific changes to DNA, enabling the development of therapeutics for agricultural biotechnology, industrial biotechnology, and basic and applied biological research.
Dren Bio is a biotechnology company with a portfolio of attractive projects focused on powerful protein engineering technologies for the depletion of cells, protein aggregates, and other disease-causing agents. It is a holding company business model aimed at creating value with multiple projects as stand-alone assets.
Totient is an AI-driven biotechnology company that leverages tertiary lymphoid structures (TLSs) to identify novel tissue-specific antigens and develop matching high-affinity antibody therapeutics. It uses machine learning and immunoinformatics technology to pull critical insights from large, complex datasets, to quickly and accurately assemble the most potent antibody candidates. The unique applicability of the Totient platform allows the company to remain flexible and develop therapeutics for cancer, autoimmune disease, infections, and viruses. It was founded in 2017 and is based in Cambridge, Massachusetts.
Symbiome offers skincare as nature intended solution which is scientifically and intentionally formulated using ancestral ingredients. It was founded in 2017 and is headquartered in San Francisco, California.
QurAlis is a clinical-stage biotechnology company that is developing precision medicines with genetically validated targets for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. Its proprietary platforms and biomarkers allow for the design and development of drugs that target disease-causing genetic alterations directly.
Pandion Therapeutics is a biotechnology company developing bispecific antibody therapeutics to achieve localized immunomodulation at the site of disease for durable, tissue-specific treatment of patients with autoimmune and inflammatory diseases, and organ transplants. Pandion’s approach has the potential to more effectively induce and sustain response and remission in patients with many autoimmune and inflammatory conditions. They aim to shift the paradigm and create a new generation of drugs with transformative efficacy and improved safety.
Arkuda Therapeutics is a biotechnology company leveraging new insights into progranulin and lysosomal biology to develop medicines to change the trajectory of neurodegenerative disease. Arkuda’s lead compounds aim to correct progranulin deficiency and lysosomal dysfunction in GRN-related frontotemporal dementia (FTD-GRN), a genetically-defined subtype of frontotemporal dementia caused by an autosomal dominant mutation in the GRN gene.
Shape Therapeutics (ShapeTX) is a biotechnology company with an end-to-end approach to RNA Gene Therapy, potentially enabling the development of cures in neurodegenerative, metabolic and rare genetic diseases through our breakthrough payload, delivery, and manufacturing platform technologies. Our vision is to facilitate adoption of these technologies throughout the industry to develop effective treatments for as many patients as possible.
Wildtype is an agtech platform based in San Francisco, California. Wildtype aims to create clean and sustainable fish and meat. They use cellular agriculture technologies to address the most pressing challenges of the generation: climate change, food security, and health. They are looking for committed scientists to fundamentally redefine how the world sources healthy and delicious meat.
Glycomine is early-stage biotech working on replacement therapies for rare diseases. There are approximately 7,000 rare disorders worldwide. Each day more are being discovered. 95% of rare diseases have not one single FDA-approved treatment. Glycomine develops therapeutics for diseases that have no treatment options.
Vaxess Technologies is developing the MIMIX™ sustained release patch technology, the easiest and most effective way to administer vaccines and therapeutics. For vaccines, the controlled release simulates the pace of a natural infection, helping the body produce a slow, strong, and enduring ramp-up of immune response, ultimately boosting a vaccine’s effectiveness. Engineered for stability, Vaxess’s patch does not require refrigeration and can be shipped to and applied in low resource settings.
CoEnzyme is a developer of therapies designed to treat orphan neurological disorders. The company develops a treatment to restore dysregulated CoEnzyme A metabolism through its CoEnzyme metabolism platform, enabling physicians to address the profound unmet medical needs.
Vedere is developing cutting-edge gene therapy products to restore functional vision to patients who have suffered vision loss from Inherited Retinal Degenerations (IRDs), as well as other causes of both genetic and non-genetic vision loss. While the vast majority of ocular gene therapies only limit the rate of inevitable vision loss, we aim to restore lost vision regardless of a patient’s underlying genetics or their stage of disease.
Nocion Therapeutics is a developer of novel pharmaceuticals intended to treat the conditions arising from neurogenic inflammation. The company is developing "nocions" which are a new kind of therapy that selectively affects actively firing nociceptors, enabling patients to provide targeted, robust and sustained relief for the treatment of serious conditions including cough, itch, pain and inflammation.
Alessa Therapeutics is a pre-clinical stage company that develops localized treatments for solid organ disease.
Tangible Science is a developer of contact lenses designed to reduce lens discomfort in dry eye diseases.The company's lenses use polymer-based coating technology that creates a bio-compatible and highly hydrated surface which prevents disruption of the natural tear film, enabling users to eliminate dry eye symptoms.
Nobell Foods uses plants to create innovative animal-based food substitutes.
Telo Therapeutics operates a biotechnology company intended to develop medicine to reverse cancer cell immortality. The company's medicine specializes in inhibiting cancer cell immortality by undergoing the immortalization process, leaving healthy cells intact, enabling patients to get cured of diseases such as cancer.
Photoswitch Biosciences is creating new tools for the next generation of questions in excitable membrane biology.
INVENIO IMAGING, Inc. is a privately held corporation founded in 2012 based on the research of Prof. Sunney Xie of the Department of Chemistry and Chemical Biology at Harvard University. Invenio is dedicated to developing a fast, reliable, simple-to-use technology for non-destructive microscopic analysis of the molecular make-up of tissues and other materials. INVENIO’s platform technology is positioned to enter the R&D microscopy market, and it is developing instrumentation for several high-value medical applications. INVENIO IMAGING Inc. acknowledges funding from the NSF and NIH SBIR programs.
Zymergen is a biotechnology company that specializes in the fields of machine learning, big data, and artificial intelligence. The company partner with nature to create materials and products across industries from agriculture to electronics, consumer care to pharmaceuticals, and more.
QurAlis is a clinical-stage biotechnology company that is developing precision medicines with genetically validated targets for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. Its proprietary platforms and biomarkers allow for the design and development of drugs that target disease-causing genetic alterations directly.
Principia Biopharma is a private, pre-clinical stage company initially focused on the discovery and development of differentiated small molecule drugs targeting inflammatory/autoimmune diseases as well as cancer. The company expects to submit an IND for its lead program in 2013 and continues to invest in additional programs and its reversible covalent platform.
Alector is combining state-of-the-art antibody technology and recent discoveries in neuroimmunology and human genetics to develop novel therapeutics for Alzheimer’s disease, other forms of dementia, and mechanistically related neurodegenerative disorders. Alector’s strategy is to efficiently generate and validate antibody drugs with unique functional properties that engage key disease-altering targets. This approach is enabled by a strategic alliance with Adimab, the industry leader in discovery and optimization of antibody therapeutics. Alector is currently developing leads for 4 major targets and anticipates taking 2 of these through pre-clinical development and IND enabling studies within 24 months. Alector has incorporated a highly integrated and lean biotechnology structure with extensive outsourcing that supports core scientific and management teams.
Cereius is a pre-clinical stage company developing novel approaches to treating solid tumor brain metastasis. Cereius’ novel radiolabeling chemistries increase the uptake and retention of radionuclides in the target tumor while minimizing uptake by normal tissues, significantly enhancing the therapeutic index and diagnostic contrast of targeting agents.
GraphWear is reinventing the way we map human health. Pioneering a no-needle, no-blood approach to disease monitoring, GraphWear’s technology offers the first genuinely non-invasive method to map patient health, unlocking a new adherence for some of the most significant chronic diseases. By empowering access to accurate and timely health information in an easy-to-use format, GraphWear aims to drive greater efficiency across diagnosis, management, and care. GraphWear is currently in clinical trials for its first target, monitoring glucose levels for diabetes, with additional potential across conditions like heart disease and cancer.
ViewPoint Therapeutics is a biotechnology company dedicated to the development of treatments for diseases of protein misfolding, including cataracts. The company's crystallin stabilizers include a small molecule that is active in preclinical models of age-related cataracts via a target-based screening and optimization effort, providing physicians with drugs to prevent or reverse protein misfolding, which is implicated in numerous common disorders of aging including cataracts, presbyopia, and neurodegenerative diseases.
Magnap provides a new minimally invasive surgical treatment for obstructive sleep apnea. They use simple magnetic force to prevent the collapsed airway associated with obstructive sleep apnea. The implant is not visible and cannot be detected unless you feel for it on their neck.
Avexegen Therapeutics develops revolutionary therapies to promote gastro-intestinal health for patients with GI disorders. They offer an approach to directly heal damaged and inflamed gut tissue in patients with crohns disease and ulcerative colitis, as well as in premature infants with necrotizing enterocolitis.
Cell Design Labs is a biotherapeutics company pioneering breakthrough science to develop disruptive cell-based therapies for cancer and other devastating diseases. Cell Design Labs leverages the power of the body’s immune system to develop smart, living therapies with the capability to treat our most challenging diseases with unprecedented power, precision, safety and durability
True North Therapeutics is a pioneering biotechnology company selectively inhibiting the Complement pathway for diseases of high unmet clinical need. The company’s lead monoclonal antibody, TNT009, targets the Classical Complement pathway, enabling selective inhibition of downstream phagocytosis, inflammation, and cell lysis. True North is currently focused on Complement-mediated rare diseases in the hematologic, kidney transplant, dermatology, and neurological space. True North was formed in 2013 as a spin-out of iPierian.
Bolt is a materials company that invents and scales materials that put the planet on a path towards a better future. Makers of b-silk(TM).
Epiodyne they are using quantitative pharmacological and behavioral techniques to translate their insights into novel medicines for patients.
Mitokinin is operates in the healthcare industry focusing on biotechnology business. It launches medicinal chemistry effort to generate kinetin analogs optimized for activating PINK1. It plans to develop the analog or optimized variants to treat Parkinson's disease.
Atreca is a biopharmaceutical that develops a technology to identify the set of antibodies produced during an immune response, without prior knowledge of an antigen. Its product candidate, ATRC-101, is a monoclonal antibody in preclinical development with a novel mechanism of action and target-derived from an antibody identified using its discovery platform.
eFFECTOR is a clinical stage biopharmaceutical company focused on pioneering the development of a new class of oncology drugs referred to as selective translation regulator inhibitors (STRIs). eFFECTOR’s STRI product candidates target the eIF4F complex and its activating kinase, mitogen-activated protein kinase 1/2 (MNK 1/2). The eIF4F complex is a central node where two of the most frequently mutated signaling pathways in cancer, the PI3K-AKT and RAS-MEK pathways, converge to activate the translation of select messenger RNA into proteins that are frequent culprits in key disease driving processes. Each of eFFECTOR’s product candidates is designed to act on a single protein that drives the expression of multiple functionally related proteins, including oncoproteins and immunosuppressive proteins in T cells, that together control tumor growth, survival and immune evasion. eFFECTOR’s lead product candidate, tomivosertib, is a MNK 1/2 inhibitor. KICKSTART, a randomized, double-blind, placebo controlled Phase 2b trial of tomivorsertib in NSCLC in combination with pembrolizumab is currently open for enrollment. Zotatifin, eFFECTOR’s inhibitor of eIF4A, is currently in the dose-escalation portion of a Phase 1/2 trial, with Phase 2a expansion cohorts expected to initiate in the second half of 2021. eFFECTOR has a global collaboration with Pfizer to develop inhibitors of a third target, eIF4E.
Vivace Therapeutics is a venture-backed start-up dedicated to discovering and developing cancer therapeutics by targeting a novel pathway. At Vivace Therapeutics, they pursue their work with passion, driven by a conviction to help people fight cancer and live life to the fullest. Based in the San Francisco Bay Area, Vivace Therapeutics is an oncology-focused portfolio-based drug discovery and development company adopting a capital-efficient and modality-indifferent approach to bring novel therapies to patients in need. Their experienced management team and world-class scientists work to advance promising drugs and therapeutic technologies that they believe can help conquer cancer.
Zephyrus Biosciences provides research tools to enable protein analysis at the single-cell level. Addressing the burgeoning single-cell analysis market, our first product, the scWestern system, enables western blotting on individual cells for the first time. Researchers will utilize Zephyrus’s products to gain new insights into the biology of cancer, stem cells, neurology, and human disease and development. It was founded in 2013 and headquartered in Berkeley, California.
Redwood Bioscience is utilizing precision protein-chemical engineering to develop optimized and novel biotherapeutics. The Company's site-specific modification technology overcomes the significant challenges associated with conjugating biologics to synthetic molecules to create homogenous hybrid biotherapeutics It was founded in 2008 and headquartered in Emeryville, California.
Symic Biomedical is a developer of matrix regulator therapeutics designed to affect matrix degradation and structure. The company's therapeutics bind to targets in the matrix, damaged in response to injury or because of disease, to inhibit pathological inflammatory responses, enabling clinicians to investigate applications in the areas of fibrosis, oncology and diseases of the central nervous system.
Circle Pharma is an early-stage biotechnology company applying proprietary computational design algorithms and innovative chemistry to develop cell-permeable macrocycle peptide therapeutics against important clinical targets. It does this through an iterative, rational design process that deploys large virtual libraries of conformationally diverse macrocycle scaffolds selected for inherent permeability. The company was founded by Matt Jacobson and Scott Lokey in 2012 and is headed by David J. Earp.
Sentieon develops and commercializes cloud-based bio-informatics solutions for the life sciences and clinical market. They develop and supply a suite of bioinformatics secondary analysis tools that process genomics data with high computing efficiency, fast turnaround time, accuracy, and consistency. Some of the released products include Sentieon DNAseq, a germline DNA pipeline; and Sentieon TNseq, for tumor-normal somatic variant detection. The company’s tools are scalable, deployable, upgradable, and software-only solutions. The Sentieon tools achieve their efficiency and consistency through optimized computing algorithm design and enterprise-strength software implementation. The company was founded by Jun Ye in 2014 and is headquartered in Mountain View, California.
SiteOne Therapeutics is a San Francisco-based company that develops novel therapeutics and diagnostics. They develop products safely, effectively, and efficiently treat acute and chronic pain without the limitations of existing therapies, such as NSAIDs and opioids. Their lead therapeutic candidates are highly selective inhibitors of a voltage-gated sodium ion channel, Naᵥ1.7, which plays a critical role in the generation and conduction of pain signals.
Pionyr Immunotherapeutics is developing cancer immunotherapies that target the tumor microenvironment to enhance the body’s antitumor immunity. The company is exploiting novel target discovery and antibody generation platform technologies to create the next generation of immuno-oncology therapeutics. The company’s approach, Myeloid Tuning™, is designed to enhance the immune system’s anti-tumor response by altering the cellular infiltrate of the tumor microenvironment with high specificity.
We are using induced pluripotent stem cells for drug discovery and development. Focused on neurodegenerative diseases such as SMA, ALS and Parkinson's, and other major unmet medical needs.